PR Newswire Asia's news > Biotechnology

 < Previous page   |   Detail   |   Print    Next page > 
     
Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
2026-08-28T    Biotechnology   Computer Networks   Computer/Electronics   Health Care/Hospital 
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Tigermed Announces 2026 Interim Results
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
2026-08-28T    Biotechnology   Medical/Pharmaceuticals 
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
2026-08-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
2026-08-28T    Biotechnology   Chemical   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.